Business Context and Reporting Period
Company: Lexaria Bioscience Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: June 29, 2020
Event: Unregistered sale of equity securities and Regulation FD disclosure regarding a new investor relations agreement.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to a specific transaction:
- Equity Issuance: 347,222 common shares issued to IRTH Communications, LLC.
- Deemed Value: $100,000 aggregate ($0.288 per share).
- Cash Compensation: $7,500 per month payable to IRTH for services.
Material Changes
The primary material change is the execution of an Investor Relations (IR) Agreement with IRTH Communications, LLC on June 29, 2020. Key terms include:
- Term: Initial one-year term with automatic renewal unless terminated 30 days prior to expiration.
- Compensation Structure: Combination of equity (347,222 shares) and monthly cash fees ($7,500).
- Regulatory Compliance: Shares are restricted securities under US and Canadian laws. The issuance required and received written consent from holders of at least 50.1% of shares issued in a prior financing (May 6, 2020).
Guidance, Outlook, and Risks
Management Commentary: The company entered the agreement to secure investor relations services. Management retains sole discretion to engage IRTH for additional services at additional costs.
Risks and Contingencies: The shares issued are restricted and bear required restrictive legends. The company is subject to ongoing cash outflows of $7,500 monthly for the duration of the agreement.
Investor Verification Checklist
- Verify the impact of the $7,500 monthly cash fee on the company's current liquidity position.
- Confirm the dilution effect of the 347,222 newly issued shares on existing shareholders.
- Review the May 6, 2020 Form 8-K to understand the prior financing and the consent obtained from major shareholders.
- Check for any subsequent filings regarding the performance of IRTH or termination of the agreement.